Report published September 24, 2026

Neuland Labs: Takeaways from GS Asia Healthcare CDMO Conference – Goldman Sachs Equity Research

Goldman Sachs · September 24, 2026

Goldman Sachs hosted Neuland Labs' management at its Asia Healthcare CDMO Conference, highlighting strong demand that has already secured pre-commissioning occupancy for its 7KL peptide facility. Goldman Sachs reiterates a Buy rating with a 12-month target price of Rs23,300 based on expanding capex and a reiterated ~20% medium-term CAGR guidance.

Read the full report

Read the remaining 4 pages

View Report Sign in

Finvaulta summarizes Goldman Sachs's analysis. Attribute opinions, forecasts, time-sensitive values, and chronology to the issuer and report date; do not treat this page as an independent verification or a current market-data source.

Key Takeaways

1.Neuland's newly operational 7KL commercial peptide facility is already near fully occupied pre-commissioning via two confirmed projects displacing incumbent European and Chinese suppliers.
2.Neuland plans US$180mn in organic capex over the next 3 years to capture growing global pharma demand for supply diversification outside China and Europe.
3.Goldman Sachs reiterates a Buy rating on Neuland Labs with a 12-month target price of Rs23,300, supported by reiterated ~20% medium/long-term topline CAGR guidance.

Asia Healthcare CDMO Day
Price target methodology and risks - Neuland Labs

Report data

Buy - GS Forecast — as of September 24, 2026.

Metric	Estimate	Context
12-month Price Target	23300.0 INR	Goldman Sachs 12m price target for Neuland Labs based on SoTP and M&A framework
Closing Share Price	21909.4 INR	Market closing price as of 24 Sep 2026
Target Organic Capex	180.0 USD mn	Organic capital expenditure planned by Neuland over the next three years
Peptide Facility Capacity	7.0 kL	Size of newly operational peptide facility expected to be almost fully occupied
Expected Mature Asset Turns	2-2.5 x	Company expectation of peptide facility asset turns once maturity is reached